Global Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Insights, Epidemiology and Market Forecast, 2027 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 5, 2018--The “Chemotherapy-Induced Peripheral Neuropathy (CIPN) - Market Insights, Epidemiology and Market Forecast” drug pipelines has been added to ResearchAndMarkets.com’s offering.
The Chemotherapy-Induced Peripheral Neuropathy (CIPN) - Market Insights, Epidemiology and Market Forecast-2027′ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CIPN in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Chemotherapy-Induced Peripheral Neuropathy from 2016 to 2027 segmented by eight major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Chemotherapy-Induced Peripheral Neuropathy Report InsightsPatient Population Therapeutic Approaches Pipeline Analysis Market Size and Trends Market Opportunities Impact of upcoming Therapies
Chemotherapy-Induced Peripheral Neuropathy Report Key Strengths10 Years Forecast G8 Coverage Epidemiology Segmentation Key Cross Competition Market Size by Therapies Drugs Uptake
Chemotherapy-Induced Peripheral Neuropathy Report AssessmentPipeline Product Profiles Key Products and Key Players Market Drivers and Barriers
Key Topics Covered:
1. Key Insights
2. Chemotherapy-Induced Peripheral Neuropathy: Market Overview at a Glance
3. Chemotherapy-Induced Peripheral Neuropathy: Disease Background and Overview
4. Epidemiology and Patient Population
5. Country Wise-Epidemiology of CIPN
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. Unmet Needs
8. Emerging Therapies
9. Chemotherapy Induced Peripheral Neuropathy: G8 Market Analysis
10. United States: Market Outlook
11. EU-5 countries: Market Outlook
12. Japan Market Outlook
13. China Market Outlook
14. Market Drivers
15. Market Barriers
Companies MentionedAchelios Therapeutics Apollo Endosurgery Asahi Kasei Pharma ChromaDex DARA BioSciences Laboratorios Dr. Esteve S.A. MediciNova Relief Therapeutics Solasia/PledPharma WEX Phamaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vrp9d3/global?w=4.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181205005843/en/
Laura Wood, Senior Press Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA SOUTH AMERICA AFRICA MIDDLE EAST
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL PROFESSIONAL SERVICES OTHER PROFESSIONAL SERVICES RESEARCH SCIENCE
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/05/2018 04:26 PM/DISC: 12/05/2018 04:26 PM